Showing results (851-860 of 1,033) with videos related to

Sort By:
Pageof 104
The Lancet. Respiratory Medicine|February 18, 2019
Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trialRobert J Lentz, Andrew D Lerner, Jasleen K Pannu, et al.
The Lancet. Respiratory Medicine|March 7, 2021
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trialFrançois-Xavier Lescure, Hitoshi Honda, Robert A Fowler, et al.
The Lancet. Respiratory Medicine|July 15, 2015
Spontaneous pneumothorax: time to rethink management?Oliver J Bintcliffe, Rob J Hallifax, Anthony Edey, et al.
The Lancet. Respiratory Medicine|June 20, 2015
Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trialUlrich H Thome, Orsolya Genzel-Boroviczeny, Bettina Bohnhorst, et al.
The Lancet. Respiratory Medicine|August 29, 2025
Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling studyElroy Boers, Meredith A Barrett, Adam V Benjafield, et al.
The Lancet. Respiratory Medicine|July 11, 2015
Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective studyStefano Guerra, Marilyn Halonen, Monica M Vasquez, et al.
The Lancet. Respiratory Medicine|July 31, 2016
Staff education, regular sedation and analgesia quality feedback, and a sedation monitoring technology for improving sedation and analgesia quality for critically ill, mechanically ventilated patients: a cluster randomised trialTimothy S Walsh, Kalliopi Kydonaki, Jean Antonelli, et al.
The Lancet. Respiratory Medicine|August 23, 2021
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trialStephan Rosenkranz, Jeremy Feldman, Vallerie V McLaughlin, et al.
The Lancet. Respiratory Medicine|August 29, 2021
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, et al.
The Lancet. Respiratory Medicine|August 29, 2021
Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trialAndreas Meiser, Thomas Volk, Jan Wallenborn, et al.
Pageof 104